TR 395 Mouse Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
PROBENECID
NTP Experiment-Test: 05030-02 Report: PEIRPT05
Study Type: CHRONIC Date: 09/04/94
Route: GAVAGE Time: 15:09:52
Facility: TSI Mason Research
Chemical CAS #: 000057669
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05030-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PROBENECID Date: 09/04/94
Route: GAVAGE Time: 15:09:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE .1G/KG .4G/KG
FEMALE LF HF
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50
Early Deaths
Moribund 9 9 9
Dead 8 7 9
Accident 1
Survivors
Terminal Sacrifice 32 31 32
Moribund 1
Other 1 1
Animals Examined Microscopically 49 49 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (44) (41) (45)
Intestine Large, Cecum (47) (14) (47)
Sarcoma 1 (2%)
Intestine Large, Colon (48) (15) (49)
Histiocytic Sarcoma 1 (7%)
Intestine Small, Ileum (47) (16) (46)
Intestine Small, Jejunum (46) (14) (44)
Histiocytic Sarcoma 1 (7%)
Liver (48) (49) (49)
Hemangiosarcoma 1 (2%)
Hemangiosarcoma, Metastatic 1 (2%)
Hepatocellular Carcinoma 2 (4%) 2 (4%) 3 (6%)
Hepatocellular Adenoma 3 (6%) 2 (4%) 10 (20%)
Hepatocellular Adenoma, Multiple 4 (8%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Pancreas (48) (19) (47)
Histiocytic Sarcoma 1 (5%)
Salivary Glands (45) (15) (49)
Stomach, Forestomach (47) (49) (49)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 3 (6%) 2 (4%) 2 (4%)
Stomach, Glandular (46) (48) (48)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (48) (15) (49)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 05030-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PROBENECID Date: 09/04/94
Route: GAVAGE Time: 15:09:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE .1G/KG .4G/KG
FEMALE LF HF
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland (48) (14) (49)
Capsule, Adenoma 1 (2%)
Adrenal Gland, Cortex (48) (14) (49)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (7%)
Islets, Pancreatic (48) (15) (46)
Adenoma 1 (2%)
Pituitary Gland (41) (13) (38)
Pars Distalis, Adenoma 1 (2%) 4 (11%)
Pars Distalis, Adenoma, Multiple 1 (2%)
Pars Intermedia, Adenoma 1 (8%)
Thyroid Gland (48) (48) (48)
Follicular Cell, Adenoma 2 (4%) 2 (4%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1) (1)
Sarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (47) (48) (50)
Cystadenoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Luteoma 1 (2%)
Uterus (48) (30) (50)
Histiocytic Sarcoma 1 (3%) 2 (4%)
Polyp Stromal 1 (3%)
Sarcoma 1 (2%)
Endometrium, Histiocytic Sarcoma 1 (3%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (48) (14) (49)
Lymph Node (43) (26) (45)
Lymph Node, Mesenteric (41) (20) (44)
Histiocytic Sarcoma 1 (5%) 1 (2%)
Spleen (48) (25) (49)
Hemangiosarcoma 1 (4%)
Hemangiosarcoma, Metastatic 1 (2%)
Thymus (42) (12) (42)
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 05030-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PROBENECID Date: 09/04/94
Route: GAVAGE Time: 15:09:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE .1G/KG .4G/KG
FEMALE LF HF
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (46) (16) (48)
Subcutaneous Tissue, Fibrosarcoma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (6%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (47) (15) (49)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (49) (23) (49)
Alveolar/Bronchiolar Adenoma 1 (2%) 4 (17%) 5 (10%)
Alveolar/Bronchiolar Carcinoma 2 (4%) 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (4%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (4%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (1) (2)
Adenoma 1 (50%)
Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (48) (19) (49)
Histiocytic Sarcoma 1 (5%)
Urinary Bladder (44) (13) (47)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(49) *(49) *(50)
Histiocytic Sarcoma 2 (4%) 3 (6%)
Lymphoma Malignant Lymphocytic 2 (4%) 1 (2%) 2 (4%)
* Number of animals with any tissue examined microscopically
Page 4
NTP Experiment-Test: 05030-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PROBENECID Date: 09/04/94
Route: GAVAGE Time: 15:09:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE .1G/KG .4G/KG
FEMALE LF HF
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS - cont
Multiple Organs *(49) *(49) *(50)
Lymphoma Malignant Mixed 2 (4%) 2 (4%) 3 (6%)
Lymphoma Malignant Undifferentiated Cell 7 (14%) 6 (12%) 2 (4%)
____________________________________________________________________________________________________________________________________
Page 5
NTP Experiment-Test: 05030-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PROBENECID Date: 09/04/94
Route: GAVAGE Time: 15:09:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE .1G/KG .4G/KG
FEMALE LF HF
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 23 21 31
Total Primary Neoplasms 26 30 49
Total Animals with Benign Neoplasms 10 10 22
Total Benign Neoplasms 10 13 30
Total Animals with Malignant Neoplasms 15 16 17
Total Malignant Neoplasms 16 17 19
Total Animals with Metastatic Neoplasms 1 1 2
Total Metastatic Neoplasm 2 1 3
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
NTP Experiment-Test: 05030-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PROBENECID Date: 09/04/94
Route: GAVAGE Time: 15:09:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE .1G/KG .4G/KG
MALE LM HM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50
Early Deaths
Dead 7 6 13
Moribund 5 19 13
Gavage Death 2
Survivors
Terminal Sacrifice 38 23 24
Animals Examined Microscopically 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large (49) (49) (47)
Anus, Squamous Cell Carcinoma 1 (2%)
Intestine Large, Cecum (48) (46) (43)
Sarcoma 1 (2%)
Intestine Small, Duodenum (48) (45) (42)
Intestine Small, Ileum (48) (44) (43)
Intestine Small, Jejunum (48) (43) (39)
Liver (50) (50) (50)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Hemangiosarcoma 2 (4%)
Hemangiosarcoma, Multiple 1 (2%) 1 (2%)
Hepatocellular Carcinoma 7 (14%) 12 (24%) 11 (22%)
Hepatocellular Adenoma 12 (24%) 2 (4%) 7 (14%)
Hepatocellular Adenoma, Multiple 3 (6%)
Histiocytic Sarcoma 1 (2%) 2 (4%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Mesentery (1) (2) (1)
Pancreas (47) (50) (50)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Acinus, Adenoma 1 (2%)
Stomach, Forestomach (49) (50) (48)
Squamous Cell Papilloma 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (49) (50) (50)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
____________________________________________________________________________________________________________________________________
Page 7
NTP Experiment-Test: 05030-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PROBENECID Date: 09/04/94
Route: GAVAGE Time: 15:09:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE .1G/KG .4G/KG
MALE LM HM
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Medulla (48) (44) (46)
Pheochromocytoma Benign 1 (2%) 1 (2%) 1 (2%)
Thyroid Gland (48) (50) (47)
Follicular Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (49) (50) (50)
Prostate (48) (46) (50)
Seminal Vesicle (49) (50) (50)
Testes (49) (50) (50)
Interstitial Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (49) (50) (50)
Hemangioma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Lymph Node (44) (45) (42)
Lumbar, Histiocytic Sarcoma 1 (2%)
Mandibular, Histiocytic Sarcoma 1 (2%)
Mediastinal, Histiocytic Sarcoma 1 (2%)
Renal, Histiocytic Sarcoma 1 (2%)
Renal, Sarcoma, Metastatic, Uncertain
Primary Site 1 (2%)
Lymph Node, Mesenteric (44) (42) (38)
Carcinoma, Metastatic, Uncertain Primary Site 1 (3%)
Histiocytic Sarcoma 1 (2%) 1 (3%)
Spleen (49) (50) (48)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Sarcoma 1 (2%)
Thymus (47) (36) (36)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 05030-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PROBENECID Date: 09/04/94
Route: GAVAGE Time: 15:09:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE .1G/KG .4G/KG
MALE LM HM
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (47) (49) (48)
Squamous Cell Papilloma 1 (2%)
Subcutaneous Tissue, Fibroma 3 (6%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%) 4 (8%) 3 (6%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%) 1 (2%)
Subcutaneous Tissue, Neurofibroma 1 (2%) 1 (2%)
Subcutaneous Tissue, Neurofibrosarcoma 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (1)
Carcinoma, Metastatic, Uncertain Primary Site 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (49) (50) (50)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (49) (50) (50)
Alveolar/Bronchiolar Adenoma 3 (6%) 4 (8%) 4 (8%)
Alveolar/Bronchiolar Carcinoma 2 (4%) 2 (4%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Carcinoma, Metastatic, Uncertain Primary Site 2 (4%)
Hemangiosarcoma, Metastatic, Skin 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 3 (6%) 7 (14%)
Histiocytic Sarcoma 2 (4%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Mediastinum, Fibrosarcoma, Early Invasion 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (4) (1)
Adenoma 2 (50%) 1 (100%)
Carcinoma 2 (50%)
____________________________________________________________________________________________________________________________________
Page 9
NTP Experiment-Test: 05030-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PROBENECID Date: 09/04/94
Route: GAVAGE Time: 15:09:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE .1G/KG .4G/KG
MALE LM HM
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (49) (50) (50)
Carcinoma, Metastatic, Uncertain Primary Site 2 (4%)
Histiocytic Sarcoma 1 (2%)
Urinary Bladder (48) (49) (47)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%) 2 (4%)
Lymphoma Malignant Lymphocytic 1 (2%) 2 (4%)
Lymphoma Malignant Mixed 1 (2%) 1 (2%) 1 (2%)
Lymphoma Malignant Undifferentiated Cell 2 (4%) 1 (2%) 2 (4%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 10
NTP Experiment-Test: 05030-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PROBENECID Date: 09/04/94
Route: GAVAGE Time: 15:09:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE .1G/KG .4G/KG
MALE LM HM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 25 26 36
Total Primary Neoplasms 35 40 48
Total Animals with Benign Neoplasms 18 10 19
Total Benign Neoplasms 20 11 21
Total Animals with Malignant Neoplasms 15 24 24
Total Malignant Neoplasms 15 29 27
Total Animals with Metastatic Neoplasms 2 3 8
Total Metastatic Neoplasm 2 3 20
Total Animals with Malignant Neoplasms 2
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 11
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------
--multipart-boundary
Content-type: text/plain
Range: bytes 60727-60727/60727
--multipart-boundary--